MCID: CHR546
MIFTS: 43

Chronic Mountain Sickness

Categories: Blood diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Chronic Mountain Sickness

MalaCards integrated aliases for Chronic Mountain Sickness:

Name: Chronic Mountain Sickness 56 74 17 71
Chronic Mountain Sickness, Susceptibility to 56
Monge's Disease 74
Monge Disease 56

Classifications:



External Ids:

OMIM 56 616182
UMLS 71 C0274294

Summaries for Chronic Mountain Sickness

OMIM : 56 Chronic mountain sickness (CMS), or Monge disease, represents a state of maladaptation to high-altitude hypoxia in a member of a population acclimatized to high altitudes. CMS is characterized by severe polycythemia and an array of neurologic symptoms, including headache, fatigue, somnolence, and depression. Often, people with CMS suffer from strokes and myocardial infarctions in early adulthood because of increased blood viscosity. Studies have shown that CMS is common in Andeans, found occasionally in Tibetans, and absent from the Ethiopian population living on the East African high-altitude plateau (summary by Zhou et al., 2013). Acute mountain sickness (see pulmonary edema of mountaineers, 178400) is experienced by unacclimatized travelers exposed to high altitude. (616182)

MalaCards based summary : Chronic Mountain Sickness, also known as chronic mountain sickness, susceptibility to, is related to acute mountain sickness and pulmonary hypertension, primary, 1. An important gene associated with Chronic Mountain Sickness is CMTS (Chronic Mountain Sickness, Susceptibility To), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Relaxin signaling pathway. The drugs Acetazolamide and Anticonvulsants have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and bone marrow, and related phenotypes are cardiovascular system and embryo

Wikipedia : 74 Chronic mountain sickness (CMS) is a disease in which the proportion of blood volume that is occupied by... more...

Related Diseases for Chronic Mountain Sickness

Diseases in the Acute Mountain Sickness family:

Chronic Mountain Sickness

Diseases related to Chronic Mountain Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 95, show less)
# Related Disease Score Top Affiliating Genes
1 acute mountain sickness 32.5 VEGFA NOS3 EDN1
2 pulmonary hypertension, primary, 1 30.3 NPPB EDN1
3 pulmonary hypertension 30.2 VEGFA NPPB NOS3 EDN1
4 hypoxia 29.6 VEGFA PDK1 EGLN3
5 pulmonary edema 29.5 NPPB NOS3 EPO EDN1
6 congestive heart failure 29.0 VEGFA NPPB NOS3 EPO EDN1
7 polycythemia 10.7
8 cyanosis, transient neonatal 10.4
9 dystrophinopathies 10.3 CASP9 CASP8
10 nephrogenic systemic fibrosis 10.3 EPO EDN1
11 tracheal calcification 10.2 NPPB EPO
12 erythrocytosis, familial, 2 10.2 EPO EGLN3
13 renal artery disease 10.2 NOS3 EPO
14 chronic thromboembolic pulmonary hypertension 10.2 NPPB EDN1
15 hypertensive encephalopathy 10.2 VEGFA EPO
16 idiopathic edema 10.2 NPPB EDN1
17 soft tissue sarcoma 10.2 VEGFA BCL2
18 testicular torsion 10.2 NOS3 BCL2
19 hypokalemia 10.2
20 posterior uveal melanoma 10.1 VEGFA BCL2
21 pulmonary valve insufficiency 10.1 NPPB EDN1
22 hemifacial spasm 10.1 VEGFA NOS3
23 migraine with or without aura 1 10.1
24 pulmonary edema of mountaineers 10.1
25 hydrops, lactic acidosis, and sideroblastic anemia 10.1
26 heart disease 10.1
27 sleep disorder 10.1
28 pulmonary venoocclusive disease 10.1 NPPB EDN1
29 sickle cell anemia 10.0 NOS3 EPO EDN1
30 coronary artery vasospasm 10.0 NOS3 EDN1
31 central sleep apnea 10.0 NPPB NOS3
32 chronic congestive splenomegaly 10.0 SST EPO
33 optic atrophy 1 10.0
34 3-methylglutaconic aciduria, type iii 10.0
35 thymoma, familial 10.0
36 restless legs syndrome 10.0
37 migraine with aura 10.0
38 chagas disease 10.0
39 patent foramen ovale 10.0
40 sensory peripheral neuropathy 10.0
41 thymoma 10.0
42 lung disease 10.0
43 splenomegaly 10.0
44 encephalopathy 10.0
45 paresthesia 10.0
46 neonatal hypoxic and ischemic brain injury 10.0
47 angina pectoris 9.9 NPPB NOS3 EDN1
48 renovascular hypertension 9.9 NPPB NOS3 EDN1
49 chronic pulmonary heart disease 9.9 NOS3 EDN1
50 systolic heart failure 9.9 NPPB NOS3 EDN1
51 exudative vitreoretinopathy 1 9.9 VEGFA NOS3 EPO
52 autonomic nervous system neoplasm 9.9 VEGFA CASP9 CASP8
53 peripheral vascular disease 9.9 VEGFA NOS3 EPO
54 peripheral nervous system neoplasm 9.9 VEGFA CASP9 CASP8
55 background diabetic retinopathy 9.9 VEGFA NOS3 EDN1
56 acute chest syndrome 9.9 VEGFA NOS3 EDN1
57 persistent fetal circulation syndrome 9.9 VEGFA NOS3 EDN1
58 hepatopulmonary syndrome 9.9 VEGFA NOS3 EDN1
59 apnea, obstructive sleep 9.9 VEGFA NOS3 EDN1
60 nonarteritic anterior ischemic optic neuropathy 9.9 VEGFA NOS3 EDN1
61 limb ischemia 9.9 VEGFA NOS3 EDN1
62 retinal vascular disease 9.8 VEGFA NOS3 EDN1
63 coronary heart disease 1 9.8 NPPB NOS3 EDN1
64 eclampsia 9.8 VEGFA NOS3 EDN1
65 diaphragmatic hernia, congenital 9.8 VEGFA NOS3 EDN1
66 carcinoid syndrome 9.8 VEGFA SST
67 renal hypertension 9.7 NPPB NOS3 EPO EDN1
68 colon adenocarcinoma 9.7 VEGFA CASP9 CASP8 BCL2
69 suppression of tumorigenicity 12 9.7 VEGFA CASP9 CASP8
70 leukemia, chronic myeloid 9.7 VEGFA EPO CASP9 BCL2
71 myeloma, multiple 9.7 VEGFA EPO CASP9 CASP8
72 angiodysplasia 9.6 VEGFA SST
73 atherosclerosis susceptibility 9.6 VEGFA NOS3 EDN1
74 vein disease 9.5 VEGFA SST EDN1
75 peripheral artery disease 9.5 VEGFA NPPB NOS3 EDN1
76 microvascular complications of diabetes 1 9.5 VEGFA SST EDN1
77 arteries, anomalies of 9.5 VEGFA NPPB NOS3 EDN1
78 coronary artery anomaly 9.5 VEGFA NPPB NOS3 EDN1
79 sleep apnea 9.4 VEGFA NPPB NOS3 EPO EDN1
80 kidney disease 9.3 VEGFA NPPB NOS3 EPO EDN1
81 chronic kidney disease 9.3 VEGFA NPPB NOS3 EPO EDN1
82 diabetic macular edema 9.3 VEGFA SST NOS3 EPO
83 lymphoma, non-hodgkin, familial 9.3 VEGFA CASP9 CASP8 BCL2
84 glucose metabolism disease 9.3 VEGFA SST NOS3
85 gastrointestinal stromal tumor 9.3 VEGFA SST CASP9 CASP8
86 hepatic vascular disease 9.3 VEGFA SST NOS3 EDN1
87 portal hypertension 9.3 VEGFA SST NOS3 EDN1
88 vascular disease 9.1 VEGFA NPPB NOS3 EPO EDN1 CASP8
89 gastric adenocarcinoma 9.1 VEGFA SST CASP9 CASP8 BCL2
90 pheochromocytoma 9.1 VEGFA SST EPO EGLN3 EDN1
91 polycystic kidney disease 9.1 VEGFA SST NOS3 EPO EDN1
92 ischemia 8.9 VEGFA NPPB NOS3 EPO EDN1 CASP9
93 myocardial infarction 8.7 VEGFA NPPB NOS3 EPO EDN1
94 hypertension, essential 8.7 VEGFA SST NPPB NOS3 EPO EDN1
95 diabetes mellitus 8.7 VEGFA SST NPPB NOS3 EPO EDN1

Graphical network of the top 20 diseases related to Chronic Mountain Sickness:



Diseases related to Chronic Mountain Sickness

Symptoms & Phenotypes for Chronic Mountain Sickness

Clinical features from OMIM:

616182

MGI Mouse Phenotypes related to Chronic Mountain Sickness:

45 (showing 7, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 BCL2 CASP8 CASP9 EDN1 EGLN3 EPO
2 embryo MP:0005380 9.97 BCL2 CASP8 CASP9 EDN1 EGLN3 EPO
3 endocrine/exocrine gland MP:0005379 9.97 BCL2 CASP8 CASP9 EDN1 EGLN3 NOS3
4 immune system MP:0005387 9.91 BCL2 CASP8 CASP9 EGLN3 EPO NOS3
5 liver/biliary system MP:0005370 9.63 CASP8 EGLN3 EPO NOS3 SENP1 VEGFA
6 muscle MP:0005369 9.5 BCL2 CASP8 EDN1 EGLN3 EPO NOS3
7 nervous system MP:0003631 9.28 BCL2 CASP8 CASP9 EDN1 EGLN3 NOS3

Drugs & Therapeutics for Chronic Mountain Sickness

Drugs for Chronic Mountain Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 31, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
2 Anticonvulsants Phase 4
3 Natriuretic Agents Phase 4
4 Carbonic Anhydrase Inhibitors Phase 4
5 diuretics Phase 4
6
Acetylcysteine Approved, Investigational Phase 1, Phase 2 616-91-1 12035
7
Cobalt Approved, Experimental Phase 1, Phase 2 7440-48-4 104729
8 Anti-Infective Agents Phase 1, Phase 2
9 Respiratory System Agents Phase 1, Phase 2
10 N-monoacetylcystine Phase 1, Phase 2
11 Free Radical Scavengers Phase 1, Phase 2
12 Expectorants Phase 1, Phase 2
13 Antidotes Phase 1, Phase 2
14 Antiviral Agents Phase 1, Phase 2
15
Digoxin Approved Phase 1 20830-75-5 30322 2724385
16 Protective Agents Phase 1
17 Anti-Arrhythmia Agents Phase 1
18
Iron Approved, Experimental 7439-89-6, 15438-31-0 23925 27284
19
Tocopherol Approved, Investigational 1406-66-2, 54-28-4 14986
20
Vitamin E Approved, Nutraceutical, Vet_approved 59-02-9 14985
21
Vitamin C Approved, Nutraceutical 50-81-7 5785 54670067
22 Tocotrienol Investigational 6829-55-6
23 Hematinics
24 Ferric Oxide, Saccharated
25 Antioxidants
26 Trace Elements
27 Nutrients
28 Micronutrients
29 Vitamins
30 Tocopherols
31 Tocotrienols

Interventional clinical trials:

(showing 6, show less)
# Name Status NCT ID Phase Drugs
1 Hypoventilation and High Altitude Chronic Polycythemia: Acetazolamide as a Possible Treatment Completed NCT00424970 Phase 4 acetazolamide
2 Randomized Controlled Trial of N-acetylcysteine and Acetazolamide in Treatment of Chronic Mountain Sickness Completed NCT01187108 Phase 1, Phase 2 N-acetylcysteine;Acetazolamide;Placebo pills
3 Phase 1 Study of Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing Not yet recruiting NCT03433833 Phase 1 Digoxin
4 Physiology Study Investigating the Effects of Supplementation and Depletion of Iron on Hypoxia-related Pulmonary Hypertension Completed NCT00952302 Iron sucrose;Normal saline;Iron sucrose;Normal saline
5 A Cohort Study of the Effect of High Altitudes on Physiological and Metabolic Markers in Adults Who Live at Qinghai-Tibet Plateau for Work Purpose Recruiting NCT03446898
6 Chronic Hypoxemia and Systemic Vascular Function Active, not recruiting NCT01182792

Search NIH Clinical Center for Chronic Mountain Sickness

Genetic Tests for Chronic Mountain Sickness

Anatomical Context for Chronic Mountain Sickness

MalaCards organs/tissues related to Chronic Mountain Sickness:

40
Lung, Heart, Bone Marrow, Bone, Brain, Testes, Endothelial

Publications for Chronic Mountain Sickness

Articles related to Chronic Mountain Sickness:

(showing 255, show less)
# Title Authors PMID Year
1
Senp1 drives hypoxia-induced polycythemia via GATA1 and Bcl-xL in subjects with Monge's disease. 61 56
27821551 2016
2
Whole-genome sequencing uncovers the genetic basis of chronic mountain sickness in Andean highlanders. 56 61
23954164 2013
3
DTI Study on Brain Structure and Cognitive Function in Patients with Chronic Mountain Sickness. 61
31852992 2019
4
Modification of the CO-rebreathing method to determine haemoglobin mass and blood volume in patients suffering from chronic mountain sickness. 61
31562838 2019
5
The impact of hypoxaemia on vascular function in lowlanders and high altitude indigenous populations. 61
31677355 2019
6
Individual chronic mountain sickness symptom is an early warning sign of cognitive impairment. 61
31770535 2019
7
Increased hypoxic proliferative response and gene expression in erythroid progenitor cells of Andean highlanders with Chronic Mountain Sickness. 61
31617751 2019
8
[The expression of VHL/HIF signaling pathway in the erythroid progenitor cells with chronic mountain sickness]. 61
31505717 2019
9
Association of Age with the Expression of Hypoxia-Inducible Factors HIF-1α, HIF-2α, HIF-3α and VEGF in Lung and Heart of Tibetan Sheep. 61
31514457 2019
10
Pulmonary arterial pressure at rest and during exercise in chronic mountain sickness: a meta-analysis. 61
31023845 2019
11
Downregulation of intrinsic apoptosis pathway in erythroblasts contributes to excessive erythrocytosis of chronic mountain sickness. 61
30683541 2019
12
Exaggerated systemic oxidative-inflammatory-nitrosative stress in chronic mountain sickness is associated with cognitive decline and depression. 61
30397919 2019
13
The Genetic Architecture of Chronic Mountain Sickness in Peru. 61
31417607 2019
14
Transcriptional profiling in the livers of rats after hypobaric hypoxia exposure. 61
30993032 2019
15
Excessive Erythrocytosis and Cardiovascular Risk in Andean Highlanders. 61
29782186 2018
16
Mitochondrial dysfunction in iPSC-derived neurons of subjects with chronic mountain sickness. 61
29357502 2018
17
The Effect of Hypoxia on Cardiovascular Disease: Friend or Foe? 61
29939783 2018
18
[Prevalence and risk factors of chronic mountain sickness in Pamirs plateau]. 61
30788941 2018
19
Intracellular pH Regulation in iPSCs-derived Astrocytes from Subjects with Chronic Mountain Sickness. 61
29438800 2018
20
[The expressions of VEGF and VEGFR signaling pathway in the bone marrow mononuclear cells with chronic mountain sickness]. 61
29690721 2018
21
Down-regulation of Inwardly Rectifying K+ Currents in Astrocytes Derived from Patients with Monge's Disease. 61
29355592 2018
22
Therapeutic Efficacy of Methazolamide Against Intermittent Hypoxia-Induced Excessive Erythrocytosis in Rats. 61
29077517 2018
23
[Study on apoptosis, cytochrome C and mitochondrial membrane potential in CD71(+) nucleated erythrocytes in patients with chronic mountain sickness]. 61
29495220 2018
24
Divergent Mitochondrial Antioxidant Activities and Lung Alveolar Architecture in the Lungs of Rats and Mice at High Altitude. 61
29670534 2018
25
New Insights into the Genetic Basis of Monge's Disease and Adaptation to High-Altitude. 61
29029226 2017
26
Association Between Plasma N-Acylethanolamides and High Hemoglobin Concentration in Southern Peruvian Highlanders. 61
28665150 2017
27
High-altitude adaptation in humans: from genomics to integrative physiology. 61
28951950 2017
28
Acetazolamide and N-acetylcysteine in the treatment of chronic mountain sickness (Monge's disease). 61
28720395 2017
29
PI3K-Akt Signal Transduction Molecules Maybe Involved in Downregulation of Erythroblasts Apoptosis and Perifosine Increased Its Apoptosis in Chronic Mountain Sickness. 61
29176544 2017
30
Natural Selection on Genes Related to Cardiovascular Health in High-Altitude Adapted Andeans. 61
29100088 2017
31
Measuring high-altitude adaptation. 61
28860167 2017
32
Reduced Cardiac Calcineurin Expression Mimics Long-Term Hypoxia-Induced Heart Defects in Drosophila. 61
28986453 2017
33
[Effect of ERK1/2 Signaling Pathway Inhibitor PD98059 on the Expression of Ras, BRaf, MEK, ERK1/2 in Marrow Nucleated Red Blood Cells of CMS Patients]. 61
29070145 2017
34
Associations of high altitude polycythemia with polymorphisms in EPAS1, ITGA6 and ERBB4 in Chinese Han and Tibetan populations. 61
29156832 2017
35
Exercise Testing, Supplemental Oxygen, and Hypoxia. 61
28590162 2017
36
[Hemoglobin changes (Hb) in miners exposed to high altitude and associated factors]. 61
28474702 2017
37
Cerebral Edema in Chronic Mountain Sickness: a New Finding. 61
28233815 2017
38
SNPs, linkage disequilibrium, and chronic mountain sickness in Tibetan Chinese. 61
28770234 2017
39
Obesity as a Conditioning Factor for High-Altitude Diseases. 61
28810235 2017
40
Effects of Acute, Profound Hypoxia on Healthy Humans: Implications for Safety of Tests Evaluating Pulse Oximetry or Tissue Oximetry Performance. 61
27529318 2017
41
Evidence for and Against Genetic Predispositions to Acute and Chronic Altitude Illnesses. 61
27500591 2016
42
Hypercapnic ventilatory response is decreased in a mouse model of excessive erythrocytosis. 61
27605561 2016
43
Dark Adaptation at High Altitude: An Unexpected Pupillary Response to Chronic Hypoxia in Andean Highlanders. 61
27454014 2016
44
Cerebral vasoconstriction reactions and plasma levels of ETBR, ET-1, and eNOS in patients with chronic high altitude disease. 61
27485004 2016
45
Erythrocyte Sedimentation Rate in Chronic Mountain Sickness. 61
27468118 2016
46
Acceptability, Safety, and Efficacy of Oral Administration of Extracts of Black or Red Maca (Lepidium meyenii) in Adult Human Subjects: A Randomized, Double-Blind, Placebo-Controlled Study. 61
27548190 2016
47
Plasma soluble erythropoietin receptor is decreased during sleep in Andean highlanders with Chronic Mountain Sickness. 61
27125843 2016
48
Chronic Mountain Sickness: Clinical Aspects, Etiology, Management, and Treatment. 61
27218284 2016
49
SENP1, but not fetal hemoglobin, differentiates Andean highlanders with chronic mountain sickness from healthy individuals among Andean highlanders. 61
26952840 2016
50
Intermittent Oxygen Inhalation with Proper Frequency Improves Overall Health Conditions and Alleviates Symptoms in a Population at High Risk of Chronic Mountain Sickness with Severe Symptoms. 61
27231170 2016
51
Sleep-Disordered Breathing and Vascular Function in Patients With Chronic Mountain Sickness and Healthy High-Altitude Dwellers. 61
26540612 2016
52
Novel Insights into Cardiovascular Regulation in Patients with Chronic Mountain Sickness. 61
27343090 2016
53
Neuroprotective Role of Intermittent Hypobaric Hypoxia in Unpredictable Chronic Mild Stress Induced Depression in Rats. 61
26901349 2016
54
PULMONARY ARTERIAL DISEASE ASSOCIATED WITH RIGHT-SIDED CARDIAC HYPERTROPHY AND CONGESTIVE HEART FAILURE IN ZOO MAMMALS HOUSED AT 2,100 M ABOVE SEA LEVEL. 61
26667539 2015
55
The Local HIF-2α/EPO Pathway in the Bone Marrow is Associated with Excessive Erythrocytosis and the Increase in Bone Marrow Microvessel Density in Chronic Mountain Sickness. 61
26625252 2015
56
New genetic and physiological factors for excessive erythrocytosis and Chronic Mountain Sickness. 61
26272318 2015
57
Research on rat models of hypobaric hypoxia-induced pulmonary hypertension. 61
26502863 2015
58
Higher androgen bioactivity is associated with excessive erythrocytosis and chronic mountain sickness in Andean Highlanders: a review. 61
25277225 2015
59
Is restless legs syndrome associated with chronic mountain sickness? 61
26026624 2015
60
Perinatal hypoxia increases susceptibility to high-altitude polycythemia and attendant pulmonary vascular dysfunction. 61
26092986 2015
61
Altitude Adaptation: A Glimpse Through Various Lenses. 61
26070057 2015
62
Vascular Endothelial Growth Factor as a Prognostic Parameter in Subjects with "Plateau Red Face". 61
25919013 2015
63
Noninvasive Assessment of Excessive Erythrocytosis as a Screening Method for Chronic Mountain Sickness at High Altitude. 61
25973777 2015
64
[Correlation between the Expression of microRNA 451 in Red Blood Cells and Chronic Mountain Sickness]. 61
25948209 2015
65
Left ventricular adaptation to high altitude: speckle tracking echocardiography in lowlanders, healthy highlanders and highlanders with chronic mountain sickness. 61
25665685 2015
66
Exaggerated pulmonary hypertension and right ventricular dysfunction in high-altitude dwellers with patent foramen ovale. 61
25375664 2015
67
Association between serum concentrations of hypoxia inducible factor responsive proteins and excessive erythrocytosis in high altitude Peru. 61
25760230 2015
68
Neonatal oxygenation, pulmonary hypertension, and evolutionary adaptation to high altitude (2013 Grover Conference series). 61
25992270 2015
69
Altered iPSC-derived neurons' sodium channel properties in subjects with Monge's disease. 61
25559931 2015
70
Sleep disturbances in long-term immigrants with chronic mountain sickness: a comparison with healthy immigrants at high altitude. 61
25462013 2015
71
Investigation of the Hepato-Protective Effects of Imdur in a Rat Model of Chronic Mountain Sickness. 61
26554240 2015
72
Genetic variation in SENP1 and ANP32D as predictors of chronic mountain sickness. 61
25225945 2014
73
Decreased plasma soluble erythropoietin receptor in high-altitude excessive erythrocytosis and Chronic Mountain Sickness. 61
25324511 2014
74
The genetic basis of chronic mountain sickness. 61
25362634 2014
75
'Ome' on the range: update on high-altitude acclimatization/adaptation and disease. 61
25099339 2014
76
Impact of increased hematocrit on right ventricular afterload in response to chronic hypoxia. 61
25170068 2014
77
The treatment of Uygur medicine Dracocephalum moldavica L on chronic mountain sickness rat model. 61
25422549 2014
78
[ACE2-Ang-(1-7)-Mas axis level of local bone marrow in chronic mountain sickness patients]. 61
25052615 2014
79
Chronic mountain sickness in Chinese Han males who migrated to the Qinghai-Tibetan plateau: application and evaluation of diagnostic criteria for chronic mountain sickness. 61
25007716 2014
80
Altitude and cold weather: are they vascular risks? 61
24806785 2014
81
Cardiovascular medicine at high altitude. 61
23892441 2014
82
Vascular endothelial growth factor-A is associated with chronic mountain sickness in the Andean population. 61
24971768 2014
83
Effects and mechanisms of acetyl-L-cysteine in rats with chronic mountain sickness with H1-NMR metabolomics methods. 61
24816079 2014
84
[Monge's disease: a forgotten eponym?]. 61
25123887 2014
85
Conduit artery structure and function in lowlanders and native highlanders: relationships with oxidative stress and role of sympathoexcitation. 61
24324004 2014
86
Carbonic anhydrase inhibitors and high altitude illnesses. 61
24146388 2014
87
Potential beneficial effects of oral administration of isoflavones in patients with chronic mountain sickness. 61
24348805 2014
88
RV contractility and exercise-induced pulmonary hypertension in chronic mountain sickness: a stress echocardiographic and tissue Doppler imaging study. 61
24269266 2013
89
Role of maca (Lepidium meyenii) consumption on serum interleukin-6 levels and health status in populations living in the Peruvian Central Andes over 4000 m of altitude. 61
23934543 2013
90
A genetic adaptive pattern-low hemoglobin concentration in the Himalayan highlanders. 61
24654529 2013
91
Prevalence of Chronic Mountain Sickness in high altitude districts of Himachal Pradesh. 61
24872667 2013
92
[Role of oxygen therapy in prevention of chronic mountain sickness]. 61
24386809 2013
93
Epidemiological study of chronic mountain sickness in natives of Spiti Valley in the Greater Himalayas. 61
24067183 2013
94
Chronic mountain sickness score was related with health status score but not with hemoglobin levels at high altitudes. 61
23770310 2013
95
Pulmonary hypertension and the right ventricle in hypoxia. 61
23625956 2013
96
Medical continuing education: reform of teaching methods about high altitude disease in China. 61
23795740 2013
97
Pulmonary hypertension and chronic mountain sickness. 61
23795731 2013
98
Serum testosterone levels and excessive erythrocytosis during the process of adaptation to high altitudes. 61
23524530 2013
99
Sleep-disordered breathing and oxidative stress in preclinical chronic mountain sickness (excessive erythrocytosis). 61
23380170 2013
100
Oxidative-nitrosative stress and systemic vascular function in highlanders with and without exaggerated hypoxemia. 61
22922469 2013
101
Adaptive modulation of adult brain gray and white matter to high altitude: structural MRI studies. 61
23874692 2013
102
Acetazolamide and chronic hypoxia: effects on haemorheology and pulmonary haemodynamics. 61
22523353 2012
103
High-altitude medicine. 61
23103737 2012
104
Exercise pathophysiology in patients with chronic mountain sickness exercise in chronic mountain sickness. 61
22302297 2012
105
Normal exercise capacity in chronic mountain sickness: how high can the hematocrit go without consequence? 61
23032448 2012
106
EPAS1 and EGLN1 associations with high altitude sickness in Han and Tibetan Chinese at the Qinghai-Tibetan Plateau. 61
22595196 2012
107
Burden of disease resulting from chronic mountain sickness among young Chinese male immigrants in Tibet. 61
22672510 2012
108
Exercise induces rapid interstitial lung water accumulation in patients with chronic mountain sickness. 61
21885723 2012
109
Ecological study of community-level factors associated with chronic mountain sickness in the young male chinese immigrant population in Tibet. 61
22343324 2012
110
Systemic vascular dysfunction in patients with chronic mountain sickness. 61
21700688 2012
111
Gene expression profiling of high altitude polycythemia in Han Chinese migrating to the Qinghai-Tibetan plateau. 61
22002498 2012
112
High serum zinc and serum testosterone levels were associated with excessive erythrocytosis in men at high altitudes. 61
21553128 2011
113
[Studies on apoptosis and caspase-8 and caspase-9 expressions of bone marrow cells in chronic mountain sickness]. 61
22339913 2011
114
Occupational health of miners at altitude: adverse health effects, toxic exposures, pre-placement screening, acclimatization, and worker surveillance. 61
21861588 2011
115
Serum testosterone levels and score of chronic mountain sickness in Peruvian men natives at 4340 m. 61
21486396 2011
116
B-type natriuretic peptide, vascular endothelial growth factor, endothelin-1, and nitric oxide synthase in chronic mountain sickness. 61
21217075 2011
117
[Hemoglobin and testosterone: importance on high altitude acclimatization and adaptation]. 61
21537776 2011
118
On the origin of Tibetans and their genetic basis in adapting high-altitude environments. 61
21386899 2011
119
Poor sleep quality predicts decreased cognitive function independently of chronic mountain sickness score in young soldiers with polycythemia stationed in Tibet. 61
21962067 2011
120
Association of chronic mountain sickness with abnormal pulmonary microcirculation: importance of adjusting predicted diffusing capacity of the lung for carbon monoxide for altitude, hemoglobin, and lung volume. 61
20823008 2010
121
High-altitude disorders: pulmonary hypertension: pulmonary vascular disease: the global perspective. 61
20522576 2010
122
Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders. 61
20534544 2010
123
Chronic mountain sickness and the heart. 61
20417348 2010
124
Exaggerated pulmonary hypertension during mild exercise in chronic mountain sickness. 61
19783668 2010
125
Lung disease at high altitude. 61
20477353 2009
126
Comprehensive geriatric assessment of elderly highlanders in Qinghai, China II: the association of polycythemia with lifestyle-related diseases among the three ethnicities. 61
20002753 2009
127
[Changes of serum angiogenesis in patients with chronic mountain sickness]. 61
21158030 2009
128
Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. 61
19809026 2009
129
Impaired acclimatization to chronic hypoxia in adult male and female rats following neonatal hypoxia. 61
19494172 2009
130
High serum testosterone levels are associated with excessive erythrocytosis of chronic mountain sickness in men. 61
19318512 2009
131
Pulmonary pressure and cardiac function in chronic mountain sickness patients. 61
18719057 2009
132
Abnormal energy regulation in early life: childhood gene expression may predict subsequent chronic mountain sickness. 61
18954447 2008
133
Effect of acetazolamide on ventilatory response in subjects with chronic mountain sickness. 61
18603026 2008
134
Adaptation and mal-adaptation to ambient hypoxia; Andean, Ethiopian and Himalayan patterns. 61
18523639 2008
135
Acetazolamide for Monge's disease: efficiency and tolerance of 6-month treatment. 61
18388356 2008
136
Adaptation to high altitude in Sherpas: association with the insertion/deletion polymorphism in the Angiotensin-converting enzyme gene. 61
18333655 2008
137
Gene expression in chronic high altitude diseases. 61
18578644 2008
138
Treatment of chronic mountain sickness: critical reappraisal of an old problem. 61
17580125 2007
139
Does chronic mountain sickness (CMS) have perinatal origins? 61
17706469 2007
140
Cardiovascular adjustments for life at high altitude. 61
17597013 2007
141
High-altitude headache. 61
17686393 2007
142
[Expression of GATA-1 and GATA-2 in the bone marrow of patients with Monge's disease]. 61
18078130 2007
143
Autonomic regulation during orthostatic stress in highlanders: comparison with sea-level residents. 61
17138623 2007
144
The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. 61
17339571 2007
145
The autonomic nervous system at high altitude. 61
17264976 2007
146
Excessive erythrocytosis in adult mice overexpressing erythropoietin leads to hepatic, renal, neuronal, and muscular degeneration. 61
16690772 2006
147
Hypoventilation in chronic mountain sickness: a mechanism to preserve energy. 61
17072073 2006
148
Chronic mountain sickness: the reaction of physical disorders to chronic hypoxia. 61
17072074 2006
149
Carotid baroreflex regulation of vascular resistance in high-altitude Andean natives with and without chronic mountain sickness. 61
16763007 2006
150
Chronic hypoxia in Andeans; are there lessons for neurology at sea level? 61
16733057 2006
151
Cerebral vasodilatation to exogenous NO is a measure of fitness for life at altitude. 61
16763189 2006
152
Gene expression, autonomic function and chronic hypoxia:lessons from the Andes. 61
16583294 2006
153
Plasma catecholamines and blood volume in native Andeans during hypoxia and normoxia. 61
16477494 2006
154
Respiratory control in residents at high altitude: physiology and pathophysiology. 61
16764526 2006
155
Evidence for a genetic basis for altitude-related illness. 61
16764528 2006
156
Chronic mountain sickness, optimal hemoglobin, and heart disease. 61
16764527 2006
157
Acetazolamide: a treatment for chronic mountain sickness. 61
16126936 2005
158
Migraine in the Andes and headache at sea level. 61
16305600 2005
159
Non-invasive measurement of circulation time using pulse oximetry during breath holding in chronic hypoxia. 61
16204801 2005
160
Cerebrovascular responses to hypoxia and hypocapnia in high-altitude dwellers. 61
15860531 2005
161
Nephropathy and retinopathy in type 2 diabetic patients living at moderately high altitude and sea level. 61
15717637 2005
162
Chronic mountain sickness on the Qinghai-Tibetan plateau. 61
15667803 2005
163
Genetic association analysis of chronic mountain sickness in an Andean high-altitude population. 61
15642663 2005
164
Cardiovascular responses to orthostatic stress in healthy altitude dwellers, and altitude residents with chronic mountain sickness. 61
15466458 2005
165
Orthostatic tolerance and blood volumes in Andean high altitude dwellers. 61
15184355 2004
166
Sports-related headache. 61
15228890 2004
167
Mini review of high altitude health problems in Ladakh. 61
15183846 2004
168
Optimal hemoglobin concentration and high altitude: a theoretical approach for Andean men at rest. 61
14672972 2004
169
Cerebral vasoreactivity in Andeans and headache at sea level. 61
15050445 2004
170
Chronic mountain sickness: recent studies of the relationship between hemoglobin concentration and oxygen transport. 61
15265336 2004
171
A Tibetan with chronic mountain sickness followed by high altitude pulmonary edema on reentry. 61
15265340 2004
172
Syndromes of subacute mountain sickness. 61
15265337 2004
173
Increased oxidative stress following acute and chronic high altitude exposure. 61
15072717 2004
174
High-altitude pulmonary hypertension: a pathophysiological entity to different diseases. 61
14680095 2003
175
Effect of domperidone on ventilation and polycythemia after 5 weeks of chronic hypoxia in rats. 61
12706060 2003
176
Gene expression in the Andes; relevance to neurology at sea level. 61
12614929 2003
177
Selected contribution: Peripheral chemoreflex function in high-altitude natives and patients with chronic mountain sickness. 61
12571149 2003
178
Selected contribution: Ventilatory response to CO2 in high-altitude natives and patients with chronic mountain sickness. 61
12571150 2003
179
Autonomic cardiovascular function in high-altitude Andean natives with chronic mountain sickness. 61
12391057 2003
180
Ventilation, autonomic function, sleep and erythropoietin. Chronic mountain sickness of Andean natives. 61
14713121 2003
181
Proposal for scoring severity in chronic mountain sickness (CMS). Background and conclusions of the CMS Working Group. 61
14713133 2003
182
Cardio-pulmonary interactions at high altitude. Pulmonary hypertension as a common denominator. 61
14713122 2003
183
Pursuing international recognition of chronic mountain sickness. 61
12855057 2003
184
[A retrospective clinical study of chronic high altitude disease complicated by acute exacerbation in high altitude environment]. 61
12757666 2003
185
Cardiopulmonary function in high altitude residents of Ladakh. 61
14672547 2003
186
Acral paresthesias in the Andes and neurology at sea level. 61
12451192 2002
187
Excessive erythrocytosis, chronic mountain sickness, and serum cobalt levels. 61
11844517 2002
188
Relationship of ovarian hormones to hypoxemia in women residents of 4,300 m. 61
11208579 2001
189
The Qinghai-Tibetan plateau: how high do Tibetans live? 61
11809089 2001
190
Human genetic adaptation to high altitude. 61
11443005 2001
191
Normal hematological values for healthy persons living at 4000 meters in Bolivia. 61
11682015 2001
192
Atrial natriuretic peptide and red cell 2,3-diphosphoglycerate in patients with chronic mountain sickness. 61
11294551 2001
193
Chronic mountain sickness. A view from the crow's nest. 61
11950154 2001
194
Current concept of chronic mountain sickness: pulmonary hypertension-related high-altitude heart disease. 61
11562018 2001
195
Neurological manifestations in chronic mountain sickness: the burning feet-burning hands syndrome. 61
10990502 2000
196
Comparative human ventilatory adaptation to high altitude. 61
10963780 2000
197
Role of the spleen in the exaggerated polycythemic response to hypoxia in chronic mountain sickness in rats. 61
10562635 1999
198
Lung disease at high altitude. 61
10634992 1999
199
International consensus group on chronic mountain sickness. 61
10635013 1999
200
ECG observations in Tibetan and Han residents of Lhasa. 61
9682900 1998
201
Polycythemic responses to hypoxia: molecular and genetic mechanisms of chronic mountain sickness. 61
9516190 1998
202
Human adaptation to high altitude: regional and life-cycle perspectives. 61
9881522 1998
203
Ventilation and hypoxic ventilatory responsiveness in Chinese-Tibetan residents at 3,658 m. 61
9390987 1997
204
Exaggerated pulmonary hypertension with monocrotaline in rats susceptible to chronic mountain sickness. 61
9216940 1997
205
Differential effects of ventilatory stimulation by sex hormones and almitrine on hypoxic erythrocytosis. 61
9094261 1997
206
Pulmonary circulation at high altitude. 61
9383818 1997
207
The role of menopause in the development of chronic mountain sickness. 61
9038995 1997
208
Breathing and brain blood flow during sleep in patients with chronic mountain sickness. 61
8872625 1996
209
Enalapril in the treatment of chronic mountain sickness. 61
11990112 1996
210
Pathophysiological effects of hemodilution in chronic mountain sickness in rats. 61
8929601 1996
211
[Upper digestive hemorrhage in the inhabitants of high altitudes in Peru]. 61
8664481 1996
212
Physical adaptation of children to life at high altitude. 61
7607274 1995
213
Migraine, polycythemia and chronic mountain sickness. 61
7828191 1994
214
Chronic mountain sickness and chronic lower respiratory tract disorders. 61
8020264 1994
215
Role of sex hormones in development of chronic mountain sickness in rats. 61
7961265 1994
216
[Acute mountain sickness and chronic mountain sickness]. 61
8007351 1994
217
Inhibitory effect of an alpha 1-adrenergic antagonist on erythropoiesis in normoxic or hypoxic mice. 61
7894046 1994
218
Pulmonary circulation in hypoxia. 61
1483782 1992
219
Pathophysiology and epidemiology of chronic mountain sickness. 61
1483802 1992
220
Chronic mountain sickness. 61
1600818 1992
221
Respiratory and hematological adaptations of young and older Aymara men native to 3600M. 61
28524404 1992
222
A case of chronic mountain sickness diagnosed by routine pulmonary function tests. 61
1909620 1991
223
Serum immunoreactive erythropoietin in high altitude natives with and without excessive erythrocytosis. 61
2055289 1991
224
Decreased ventilation and hypoxic ventilatory responsiveness are not reversed by naloxone in Lhasa residents with chronic mountain sickness. 61
2252247 1990
225
Chronic mountain sickness in Tibet. 61
2513594 1989
226
[Sperm count and seminal biochemistry of high altitude inhabitants and patients with chronic altitude sickness]. 61
2619313 1989
227
[Human life at high altitudes: myths and realities]. 61
2699275 1989
228
Subacute infantile mountain sickness. 61
2969047 1988
229
Effects of chronic normobaric hypoxic and hypercapnic exposure in rats: prevention of experimental chronic mountain sickness by hypercapnia. 61
3666983 1987
230
Hepatic heme and drug metabolism in rats with chronic mountain sickness. 61
3094379 1986
231
Acute and chronic pulmonary pressor responses to hypoxia: the role of blunting in acclimatization. 61
3704382 1986
232
Responses of blood volume and red cell mass in two strains of rats acclimatized to high altitude. 61
4070838 1985
233
Calcium channel blockers in hypoxic pulmonary hypertension. 61
3976691 1985
234
The role of pulmonary vascular responses to chronic hypoxia in the development of chronic mountain sickness in rats. 61
6240752 1984
235
Ventilatory responses and blood gases in susceptible and resistant rats to high altitude. 61
6240751 1984
236
Strain and sex differences in the cardiopulmonary adaptation of rats to high altitude. 61
6237368 1984
237
Chronic mountain sickness at an elevation of 2,000 meters. 61
6368145 1984
238
Hemoglobin levels in a Himalayan high altitude population. 61
6731601 1984
239
Effect of acetazolamide on normoxic and hypoxic exercise in humans at sea level. 61
6662767 1983
240
[Medicine of the Andes (chronic mountain sickness)]. 61
6660069 1983
241
Chronic mountain sickness. 61
1011412 1976
242
[Mental and neurological disorders in chronic mountain sickness]. 61
1013248 1976
243
Age as a cause of chronic mountain sickness (Monge's disease). 61
1165128 1975
244
Pathology of chronic mountain sickness. 61
4787982 1973
245
On the pathology of chronic mountain sickness. 61
4718567 1973
246
Chronic cor pulmonale due to loss of altitude acclimatization (chronic mountain sickness). 61
4253583 1971
247
Cardio-respiratory studies in chronic mountain sickness (Monge's syndrome). 61
5140341 1971
248
Renal function in high-altitude natives and in natives with chronic mountain sickness. 61
5837586 1965
249
Effect of blood-letting on chronic mountain sickness. 61
5885930 1965
250
RENAL EXCRETION OF BICARBONATE IN HIGH ALTITUDE NATIVES AND IN NATIVES WITH CHRONIC MOUNTAIN SICKNESS. 61
14234826 1964
251
CHRONIC MOUNTAIN SICKNESS. 61
14142743 1964
252
A case of chronic mountain sickness in the United States: clinical, physiologic and electrocardiographic observations. 61
13571262 1958
253
[Chronic mountain sickness in cows (brisket disease); hematological & anatomopathological study]. 61
13411562 1955
254
[Chronic mountain sickness in America]. 61
13207756 1953
255
LIFE IN THE ANDES AND CHRONIC MOUNTAIN SICKNESS. 61
17757318 1942

Variations for Chronic Mountain Sickness

Expression for Chronic Mountain Sickness

Search GEO for disease gene expression data for Chronic Mountain Sickness.

Pathways for Chronic Mountain Sickness

Pathways related to Chronic Mountain Sickness according to GeneCards Suite gene sharing:

(showing 30, show less)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 VEGFA NOS3 EPO CASP9 CASP8 BCL2
2
Show member pathways
12.5 VEGFA SST NOS3 EDN1 BCL2
3
Show member pathways
12.47 VEGFA PDK1 EGLN3 BCL2
4
Show member pathways
12.3 NOS3 CASP9 CASP8 BCL2
5 12.22 VEGFA EPO EGLN3 EDN1 CASP9 CASP8
6
Show member pathways
12.07 CASP9 CASP8 BCL2
7 11.97 CASP9 CASP8 BCL2
8 11.97 VEGFA CASP9 CASP8 BCL2
9
Show member pathways
11.9 CASP9 CASP8 BCL2
10
Show member pathways
11.89 CASP9 CASP8 BCL2
11
Show member pathways
11.85 CASP9 CASP8 BCL2
12 11.81 VEGFA NOS3 EDN1 BCL2
13
Show member pathways
11.77 PDK1 EPO BCL2
14 11.74 NOS3 CASP9 BCL2
15
Show member pathways
11.69 NOS3 CASP9 CASP8
16
Show member pathways
11.68 CASP9 CASP8 BCL2
17 11.62 VEGFA NOS3 EDN1 BCL2
18 11.61 CASP9 CASP8 BCL2
19 11.54 NOS3 CASP9 CASP8
20 11.48 VEGFA PDK1 CASP9
21 11.37 VEGFA EPO EGLN3 EDN1
22 11.36 CASP9 CASP8 BCL2
23
Show member pathways
11.29 CASP9 CASP8 BCL2
24 11.27 CASP9 CASP8 BCL2
25 11.2 VEGFA EPO EDN1
26 11.2 VEGFA PDK1 NOS3 EPO EGLN3 EDN1
27 11.19 VEGFA NOS3 EPO EDN1
28 11.11 VEGFA EPO EGLN3
29 11.03 VEGFA NOS3
30 11 CASP9 BCL2

GO Terms for Chronic Mountain Sickness

Biological processes related to Chronic Mountain Sickness according to GeneCards Suite gene sharing:

(showing 20, show less)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.92 EPO EGLN3 CASP9 CASP8 BCL2
2 cell surface receptor signaling pathway GO:0007166 9.76 SST NPPB EDN1 CASP8
3 cellular response to hypoxia GO:0071456 9.75 VEGFA EDN1 BCL2
4 kidney development GO:0001822 9.74 VEGFA CASP9 BCL2
5 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.65 VEGFA EPO EGLN3
6 regulation of blood pressure GO:0008217 9.61 NPPB NOS3 EDN1
7 regulation of blood vessel diameter GO:0097746 9.59 NPPB NOS3
8 macrophage differentiation GO:0030225 9.58 VEGFA CASP8
9 intrinsic apoptotic signaling pathway in response to oxidative stress GO:0008631 9.56 PDK1 BCL2
10 positive regulation of renal sodium excretion GO:0035815 9.55 NPPB EDN1
11 positive regulation of urine volume GO:0035810 9.54 NPPB EDN1
12 response to dexamethasone GO:0071548 9.51 EPO EDN1
13 body fluid secretion GO:0007589 9.49 NPPB EDN1
14 response to hypoxia GO:0001666 9.46 VEGFA EPO EGLN3 EDN1
15 negative regulation of myeloid cell apoptotic process GO:0033033 9.4 EPO BCL2
16 response to cobalt ion GO:0032025 9.37 CASP9 CASP8
17 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.32 NOS3 EDN1
18 negative regulation of calcium ion transport into cytosol GO:0010523 9.26 EPO BCL2
19 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.26 SENP1 EGLN3 CASP9 CASP8
20 response to lipopolysaccharide GO:0032496 9.02 NOS3 EPO EDN1 CASP9 CASP8

Molecular functions related to Chronic Mountain Sickness according to GeneCards Suite gene sharing:

(showing 4, show less)
# Name GO ID Score Top Affiliating Genes
1 cysteine-type peptidase activity GO:0008234 9.43 SENP1 CASP9 CASP8
2 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 9.16 CASP9 CASP8
3 cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097199 8.96 CASP9 CASP8
4 hormone activity GO:0005179 8.92 SST NPPB EPO EDN1

Sources for Chronic Mountain Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....